Radiotherapy Combination Therapy Shows Promise in Treating Non-Small Cell Lung Cancer

Strategic Insights -

Research conducted by Qingdao Municipal Hospital in Shandong, People's Republic of China, has shown that combining radiotherapy with anti-angiogenic therapy, immune checkpoint inhibitors, and chemotherapy can be effective in prolonging the survival of patients with advanced non-small cell lung cancer (NSCLC). The study, published in Frontiers in Oncology, involved 74 patients who received at least two cycles of quadruple therapy. The results suggest that the addition of radiotherapy can play a positive role in extending progression-free survival (PFS) and overall survival (OS) in patients with advanced NSCLC.

Key Takeaways:

  • The study found that the incidence rate of adverse events such as radiation-related pneumonitis, pneumonia, thrombocytopenia, cough, panting, fatigue, and radiodermatitis were significantly higher in patients receiving radiotherapy.
  • A survival analysis comparing the experimental and control groups revealed that the addition of radiotherapy played a positive role in extending PFS and OS, with statistically significant results observed for OS (HR(95%CI)=0.51[0.283, 0.919]; p=0.019).
  • The risk of radiation-related pneumonitis was significantly higher than in the control group (p=0.001) and was associated with a negative impact on prognosis; a similar trend was also observed for pneumonia (p=0.041) and thrombocytopenia (p=0.001).
  • Sequential radiotherapy after quadruple therapy can prolong survival in patients with advanced NSCLC.
  • The study concluded that special attention should be paid to treatment-related side effects such as pneumonitis, pneumonia, and thrombocytopenia, which may negatively affect prognosis.

Statistics:

  • 74 patients were enrolled in the study.
  • The occurrence rate of adverse events in patients receiving radiotherapy was significantly higher than in the control group.
  • The hazard ratio (HR) for OS was 0.51 (95% CI: 0.283, 0.919) in favor of the experimental group (p=0.019).
  • The risk of radiation-related pneumonitis was 10 times higher in the experimental group than in the control group (p=0.001).
  • The study focused on patients with advanced NSCLC who had received at least two cycles of quadruple therapy.

Sources:

  • Efficacy and safety of thoracic radiotherapy combined with anti-angiogenic therapy and immunochemotherapy for advanced non-small cell lung cancer patients: a retrospective study. Frontiers in Oncology, 2025;15:1640306.
  • Frontiers in Oncology can be contacted at: Frontiers Media Sa, Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland.